Literature DB >> 32212064

Does ischemia-modified albumin level predict severity of obstructive sleep apnea?

Mustafa Düger1, Ekrem Cengiz Seyhan2, Mehmet Zeki Günlüoğlu1, Mustafa Bolatkale3, Mehmet Akif Özgül4, Demet Turan4, Efsun Uğur4, Gözde Ülfer5.   

Abstract

OBJECTIVE AND AIM: Ischemia-modified albumin (IMA) is a newly recognized marker of chronic inflammation used to evaluate oxidative stress status in patients with various diseases. We explored the possible relationship between IMA levels and obstructive sleep apnea (OSA).
METHODS: In this retrospective study, 169 of 216 sequential patients being evaluated for suspicion of OSAS met inclusion criteria. Polysomnography confirmed OSA in 86 patients (51%) while 81 patients (49%) without OSA were categorized as control subjects. All study participants were tested for blood IMA level, neutrophil/lymphocyte ratio (NLR), C-reactive protein (CRP) level, and red blood cell distribution width (RDW).
RESULTS: The serum IMA level was significantly higher in patients with OSAS than controls (p = 0.008). The serum IMA level increased significantly as OSAS severity increased (r = 0.50, p < 0.001) and was positively correlated with the AHI (r = 0.41, p < 0.001), CRP level (r = 0.31, p = 0.004), body mass index (r = 0.24, p = 0.022), RDW (r = 0.31, p = 0.03), oxygen desaturation index (ODI) (r = 0.22, p = 0.02), and negatively correlated with the hemoglobin concentration (r = - 0.28, p = 0.04) and minimum hemoglobin oxygen saturation (SpO2) (r = - 0.25, p = 0.02). Receiver operator curve (ROC) analysis showed that the optimal serum IMA, CRP, RDW, and NLR values were not different for predicting OSAS diagnosis (areas under the curves (AUC) = 0.62, 0.59, 0.60, and 0.43, respectively). However, the serum IMA level was superior in reflecting OSAS severity (AUC = 0.78) compared to CRP, RDW, and NLR values (AUC = 0.61, 0.53, and 0.51, respectively) (all p < 0.001).
CONCLUSION: Like other markers of inflammation, blood IMA levels were significantly elevated in patients with OSA. However, blood IMA level was a better predictor of disease severity than the other markers.

Entities:  

Keywords:  Apnea-hypopnea index; Ischemia-modified albumin; Obstructive sleep apnea syndrome; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32212064     DOI: 10.1007/s11325-020-02038-9

Source DB:  PubMed          Journal:  Sleep Breath        ISSN: 1520-9512            Impact factor:   2.816


  4 in total

1.  Red cell distribution width in patients with obstructive sleep apnea syndrome.

Authors:  Savas Ozsu; Yasin Abul; Ayhan Gulsoy; Yilmaz Bulbul; Selcuk Yaman; Tevfik Ozlu
Journal:  Lung       Date:  2012-02-07       Impact factor: 2.584

Review 2.  Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?

Authors:  S Ryan; C T Taylor; W T McNicholas
Journal:  Thorax       Date:  2009-07       Impact factor: 9.139

3.  Neutrophil-to-lymphocyte ratio in obstructive sleep apnea; a multi center, retrospective study.

Authors:  N Altintas; E Çetinoğlu; M Yuceege; A N Acet; A Ursavas; H Firat; M Karadag
Journal:  Eur Rev Med Pharmacol Sci       Date:  2015-09       Impact factor: 3.507

4.  Ischemia-modified albumin in type 2 diabetic patients with and without peripheral arterial disease.

Authors:  Shao-gang Ma; Chun-ling Wei; Bing Hong; Wei-nan Yu
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  4 in total
  2 in total

Review 1.  Evaluation of Blood Levels of C-Reactive Protein Marker in Obstructive Sleep Apnea: A Systematic Review, Meta-Analysis and Meta-Regression.

Authors:  Mohammad Moslem Imani; Masoud Sadeghi; Farid Farokhzadeh; Habibolah Khazaie; Serge Brand; Kenneth M Dürsteler; Annette Brühl; Dena Sadeghi-Bahmani
Journal:  Life (Basel)       Date:  2021-04-19

2.  Increase in Ischemia-Modified Albumin and Pregnancy-Associated Plasma Protein-A in COVID-19 Patients.

Authors:  Belén G Sanchez; Jose M Gasalla; Manuel Sánchez-Chapado; Alicia Bort; Inés Diaz-Laviada
Journal:  J Clin Med       Date:  2021-11-23       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.